

**Please cite the Published Version**

Albayati, Samara, Li, Nailin, Unsworth, Amanda  and Liverani, Elisabetta (2022) Platelet-lymphocyte co-culture serves as an ex vivo platform of dynamic heterotypic cross-talk. *Journal of Cell Communication and Signaling*, 16 (4). pp. 661-675. ISSN 1873-9601

**DOI:** <https://doi.org/10.1007/s12079-022-00676-0>

**Publisher:** Springer (part of Springer Nature)

**Version:** Accepted Version

**Downloaded from:** <https://e-space.mmu.ac.uk/629316/>

**Additional Information:** This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature's AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: <http://dx.doi.org/10.1007/s12079-022-00676-0>

**Enquiries:**

If you have questions about this document, contact [openresearch@mmu.ac.uk](mailto:openresearch@mmu.ac.uk). Please include the URL of the record in e-space. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from <https://www.mmu.ac.uk/library/using-the-library/policies-and-guidelines>)

1  
2  
3 **Platelet-lymphocyte co-culture serves as an *ex vivo* platform of**  
4 **dynamic heterotypic cross-talk**  
5  
6  
7  
8  
9

10  
11 Samara Albayati<sup>1</sup>, Nailin Li<sup>2</sup>, Amanda J. Unsworth<sup>3</sup> and Elisabetta Liverani<sup>1</sup>  
12

13 <sup>1</sup> Sol Sherry Thrombosis Research Center, Temple University School of Medicine,  
14 Temple University Hospital, Philadelphia, Pennsylvania, United States of America

15 <sup>2</sup> Karolinska Institutet, Department of Medicine-Solna, Clinical Epidemiology Unit,  
16 Clinical Pharmacology Group, Stockholm, Sweden. <sup>3</sup> Department of Life Sciences,  
17 Faculty of Science and Engineering, Manchester Metropolitan University, John  
18 Dalton Building, Manchester M1 5GD, UK.

19  
20  
21  
22  
23 **Corresponding Author:**  
24

25 Elisabetta Liverani, PhD  
26 Department of Pharmaceutical Sciences,  
27 College of Health Professions,  
28 North Dakota State University,  
29 Fargo, ND 58102, USA  
30 Tel: 1-701-231-1098  
31 Email: [elisabetta.liverani@ndus.edu](mailto:elisabetta.liverani@ndus.edu)

1 **Abstract**

2  
3 Platelets are well known for their roles in hemostasis and thrombosis, and are  
4 increasingly recognized for their abilities to interact with white blood cells during  
5 inflammatory diseases, via secreted soluble factors as well as cell-cell contact.  
6 This interaction has been investigated in animal models and patient samples and  
7 has shown to be implicated in patient outcomes in several diseases. Platelet-  
8 leukocyte co-cultures are widely used to study platelet-leukocyte interactions *ex*  
9 *vivo*. However, there is a paucity with regard to the systematic characterization of  
10 cell activation and functional behaviors of platelets and leukocytes in these co-  
11 cultures. Hence we aimed to characterize a model of platelet-leukocyte co-culture  
12 *ex vivo*. Human peripheral blood mononuclear cell (PBMC) and platelets were  
13 isolated and co-cultured for 5 days at 37°C in the presence or absence of anti-  
14 CD3/CD28 antibodies or PHA. We evaluated PF-4 secretion and p-selectin  
15 expression in platelets as markers of platelet activation. Lymphocyte activation  
16 was assessed by cell proliferation and cell population phenotyping, in addition to  
17 platelet-lymphocyte aggregation. Platelet secretion and p-selectin expression is  
18 maintained throughout the co-culture, indicating that platelets were viable and  
19 reactive over the 5 days . Similarly PBMCs were viable and maintained proliferative  
20 capacity. Finally, dynamic heterotypic conjugation between platelets and T  
21 lymphocytes was also observed throughout co-culture (with a peak at days 3 and  
22 4) upon T lymphocyte activation. In conclusion, this *in vitro* model can successfully  
23 mimic the *in vivo* interaction between platelets and T lymphocytes, and can be  
24 used to confirm and/or support *in vivo* results.

25  
26 **Key words:** platelets, leukocytes, heterotypic conjugation, secretion, co-culture,  
27 cross-talk.

28  
29 **Abbreviations:**

30 PBMCs: peripheral blood mononuclear cells; PBS: phosphate-buffered saline;  
31 Phytohemagglutinin: PHA; 2MeSADP: 2-methylthio-ADP.

32

1 **Introduction**

2 Platelets are well known for their roles in hemostasis and thrombosis, and are also  
3 increasingly recognized for their ability to modulate immune responses through  
4 interactions with immune cells [1, 2]. Platelet interactions with neutrophils have  
5 been thoroughly studied, and there is growing evidence that activated platelets  
6 directly interact with other leukocytes [3], such as T and B lymphocytes [4],  
7 monocytes [2] and dendritic cells [1]. Platelet activation leads to platelet shape  
8 changes, mobilization of receptors and adhesion proteins and secretion of various  
9 secondary mediators that amplify platelet activation and coagulation, in addition to  
10 inflammatory mediators such as transforming growth factor  $\beta$  (TGF- $\beta$ ), RANTES,  
11 platelet factor 4 (PF4), and interleukin 1  $\beta$  (IL-1 $\beta$ ) that regulate activation and  
12 recruitment of inflammatory cells [5, 6]. Both platelet-secreted soluble factors and  
13 platelet surface-expressed proteins contribute significantly to immune cell  
14 activation [7]. Previous studies in a variety of animal models have shown that either  
15 platelet depletion or interference with platelet activation can result in reduced  
16 inflammation levels [8-11].

17 Activated platelets have been shown to interact directly with T lymphocytes during  
18 inflammation both *in vitro* and *in vivo*. For instance, platelets form aggregates with  
19 CD4+ T cells in circulation in various clinical settings, such as rheumatoid arthritis  
20 [12] and acquired immune deficiency syndrome (AIDS) [13]. Activated platelets  
21 have also been shown to enhance proliferation and activation of Tregs *in vitro* [14].  
22 Platelets were found to alter T-cell population sizes in an animal model of burn  
23 injury [15] and we have previously described that platelets alter Treg population

1 size and function in a stimulation-dependent manner *in vivo* in an animal model of  
2 sepsis and *in vitro* [16], using the model characterised in this paper. All these  
3 experimental results indicate that platelet interactions with T cells are important  
4 during inflammatory conditions, yet the nature of these interactions is still unclear.  
5 Platelet-leukocyte co-cultures have been widely used to study platelet-leukocyte  
6 interactions *ex vivo* [14, 16, 17]. However, there is paucity with regard to the  
7 systematic characterization of cell activation and functional behaviors of platelets  
8 and leukocytes in these co-cultures. This study aims to characterize the *ex vivo*  
9 platelet-leukocyte co-culture model and we show that this models mimics platelet-  
10 leukocyte interaction *in vivo*. Furthermore, this co-culture system supports *ex vivo*  
11 evaluations of platelet-leukocyte interactions over time under defined conditions,  
12 to interrogate the effects of platelet aging during inflammation. Our data show that  
13 both PBMCs and platelets are viable and interact with each other throughout co-  
14 culture, mediated by both soluble factors and cell-cell interaction. Interestingly,  
15 platelets are found to be capable of secretion and activation throughout 5 days of  
16 co culture. Overall, this model can be used as an *ex vivo* model to confirm and/or  
17 support *in vivo* results.

18

## 19 **Material and methods**

20

### 21 *Materials*

22 All reagents were of analytical grade and were obtained from Thermo Fisher  
23 Scientific (Waltham, MA) unless stated otherwise. Anti-human CD3 and anti-  
24 human CD28 were purchased from TONBO bioscience (San Diego, CA). Triton-

1 X100, phosphate-buffered saline (PBS) and 2-Methylthio ADP (2MeSADP) were  
2 purchased from Sigma-Aldrich (St. Louis, MO). Ficoll-Paque was from GE  
3 Healthcare Bio-Sciences AB (Uppsala, SE). Anti-human CD4 (FITC-conjugated;  
4 clone OKT4), anti-human CD8 (PE-conjugated; clone HIT8a) and anti-human  
5 CD62P (p-selectin) (FITC-conjugated; clone AK-4) antibodies were obtained from  
6 eBioscience (San Diego, CA). Rat IgG2a  $\kappa$  isotype control FITC (clone eBR2a), rat  
7 IgG2b  $\kappa$  isotype control PE (clone eB149/10H5), mouse IgG1  $\kappa$  isotype control  
8 (clone P.3.6.2.8.1) were purchased from eBioscience (San Diego, CA). AR-  
9 C69931MX tetrasodium salt was obtained from TOCRIS (Pittsburgh, PA). Alamar  
10 Blue Cell Viability Reagent was purchased from Invitrogen (Waltham, MA).

11

12

### 13 *Platelet isolation*

14

15 Human blood (50mL) was obtained from healthy volunteers who gave informed  
16 consent to participate in the study. The study was approved by the Institutional  
17 Review Board of Temple University School of Medicine (#0377). Blood was diluted  
18 with one-sixth volume of acid-citrate-dextrose (2.5 g of sodium citrate, 1.5 g of citric  
19 acid, and 2.0 g of glucose in 100 ml of deionized water). Platelet-rich plasma (PRP)  
20 was prepared by centrifugation at  $230 \times g$  for 20 minutes at room temperature. The  
21 PRP obtained was then centrifuged at  $980 \times g$  for 10 minutes at room temperature  
22 and the platelet pellet resuspended in Tyrode's buffer (138 mM NaCl, 2.7 mM KCl,  
23 2 mM  $MgCl_2$ , 0.42 mM  $NaH_2PO_4$ , 5 mM glucose, and 10 mM HEPES; pH 7.4)  
24 containing 0.2 units/ml apyrase. Cells were counted using the Hemavet  
25 Multispecies Hematology System (Drew Scientific, Inc., Oxford, CT). Platelet

1 viability and functions were tested after isolation (day 0) and every day from day 1  
2 to 5.

3

#### 4 *Human peripheral blood mononuclear cell isolation*

5 Blood samples after PRP preparation were diluted with RPMI 1640 medium (1:1),  
6 layered over Ficoll-Paque (10 mL for 50 mL of diluted blood), and centrifuged at  
7  $300 \times g$  for 30 minutes at room temperature without break nor acceleration. Cells  
8 were collected from the interphase layer, then washed twice in HBSS and counted  
9 using the Hemavet Multispecies Hematology System (Drew Scientific, Inc., Oxford,  
10 CT). Cells were transferred to RPMI 1640 medium supplemented with penicillin-  
11 streptomycin (each at 0.8 mM) and glutamine (2 mM), and maintained at 37°C in  
12 a humidified atmosphere containing 5% CO<sub>2</sub>. PBMC proliferation was tested after  
13 isolation (day 0) and every day from day 1 to 5.

14

#### 15 *Platelet and PBMC Co-culture*

16 PBMCs and platelets were seeded at the respective concentrations of  
17  $1 \times 10^6$  cells/mL and  $2.5 \times 10^8$  cells/mL, either alone or together, i.e. co-cultured at  
18 the ratio of 1: 250. The cells were cultured without stimulation or activated via  
19 incubation with either phytohemagglutinin (PHA, 5µg/mL) or anti-CD3/CD28  
20 (5µg/mL each) antibodies. PHA was added to the cells immediately after seeding.  
21 For the polyclonal stimulation, culture plates were pre-coated with anti-CD3  
22 antibody (5µg/mL in PBS, 200µL/well, and incubation overnight), and anti-human  
23 CD28 antibody was added (5µg/mL as final concentration) after cells were plated

1 into the wells. PBMCs and platelets were maintained for 5 days at 37°C and 5%  
2 CO<sub>2</sub> in in RPMI 1640 media, fully supplemented with penicillin- streptomycin (each  
3 at 0.8 mM) and L-glutamine (2 mM). PBMCs and platelets were monitored after  
4 isolation (day 0) and every day from day 1 to 5.

5

#### 6 *Platelet viability*

7 Platelets were collected from the co-culture, washed and then incubated with anti-  
8 human Annexin V antibody from a Annexin V-FITC apoptosis detection kit Sigma-  
9 Aldrich (St. Louis, MO) to detect phosphatidylserine exposure. Cells were analyzed  
10 by flow cytometry using a FACSCalibur analyzer (Becton Dickinson), and data  
11 were analyzed with FlowJo software (Tree Star, Inc. Ashland, OR). Mouse IgG1 κ  
12 isotype control (clone P.3.6.2.8.1) was included as a negative control for antibody  
13 binding.

14

#### 15 *Cell proliferation*

16 PBMC proliferation was analyzed using Alamar Blue cell viability reagent as per  
17 manufacturer instructions. Both T cells (derived from PBMCs) cultured alone and  
18 with platelets were analyzed daily from day 1 to day 5. Cells were incubated with  
19 Alamar Blue (10µL per 100µL of cell culture) for 4 hours at 37 °C and 5% CO<sub>2</sub>. The  
20 absorbance of each samples was measured using a micro-plate reader at a  
21 wavelength of 570 nm. Data are shown as absorbance readings.

22

#### 23 *P-selectin surface expression in platelets*




1 Surface expression of p-selectin was measured using flow cytometry after isolation  
2 (day 0) and daily during 5-day cell cultures. Briefly, platelets ( $2.5 \times 10^8$  cells/mL;  
3 100  $\mu$ l) were incubated with 2-methylthio-ADP (2MeSADP, 100nM) for 5 minutes  
4 at 37°C with gentle stirring. A negative unstimulated control was run alongside the  
5 activated platelet samples. Cells were centrifuged ( $980 \times g$  for 10 minutes) and the  
6 supernatant was collected for PF-4 and soluble p-selectin detection. Platelets were  
7 then resuspended in Tyrode's buffer containing 0.2 units/ml apyrase and incubated  
8 with FITC-conjugated anti-human CD62P (p-selectin) antibody for 1 hour at RT,  
9 the assay was then stopped and fixed by the addition of 4% of paraformaldehyde  
10 prior to flow cytometry analysis. From day 1 to 5, p-selectin surface expression  
11 was measured in platelets cultured alone or with PBMCs. The platelets that were  
12 cultured alone (100 $\mu$ L) were incubated with 2Mes-ADP (100nM) for 5 minutes at  
13 37°C in stirring conditions. ADP-activated platelets (100 $\mu$ L), inactivated platelets  
14 (100 $\mu$ L), or platelet-PBMC co-culture (100 $\mu$ L) were then incubated with FITC-  
15 conjugated antibody anti-human CD62P (p-selectin) for 1 hour at RT. Cells were  
16 centrifuged ( $980 \times g$  for 10 minutes) and the supernatant was collected for PF-4  
17 and soluble p-selectin detection. Cells were then resuspended in Tyrode's buffer  
18 containing 4% of paraformaldehyde prior to flow cytometry analysis. The  
19 supernatant was collected for PF-4 and soluble p-selectin detection. Cells were  
20 then acquired using a Becton Dickinson FACS Vantage cell sorter and analyzed  
21 using the Flow Jo software (Figure 1).

22

23 **Figure 1: Flow cytometric gating strategy to identify T cell populations, p-selectin**  
24 **surface expression and platelet-T cell aggregates.** The histograms show the isotype

1 control (black) and the antibody labelled cells (red). The gate was selected based on the  
2 isotype control with all the events in the gate (red) considered positive cells.

3



4

5

6 *CD4+ and CD8+ cell population*

7 CD4 and CD8 phenotyping were measured via flow cytometry. Isolated PBMC (0.5

8 x 10<sup>6</sup> cells) were incubated with FITC-conjugated anti-human CD4 and PE-

9 conjugated anti-human CD8 antibodies (1:100 dilution) for 1 hour at RT. Cells were

10 washed and kept in PBS at 4°C prior to analysis. Cells were then acquired using

1 a Becton Dickinson FACS Vantage cell sorter and analyzed using the Flow Jo  
2 software. The total number of events acquired was 20,000 for each sample. Data  
3 are shown as a % of positive events as compared to the total number of events  
4 acquired (20,000) (Fig 1). Rat IgG2a  $\kappa$  isotype control FITC (clone eBR2a), rat  
5 IgG2b  $\kappa$  isotype control PE (clone eB149/10H5) were included as negative isotype  
6 controls.

7

### 8 *Platelet-CD4+ and CD8+ T cell aggregate formation*

9

10 The formation of platelet-CD4+ and platelet-CD8+ T cell aggregates was  
11 analyzed daily across the 5 day co-culture using flow cytometry. Platelet-PBMC  
12 co-culture (100 $\mu$ l) were incubated with antibodies (diluted 1:50) against human  
13 CD41 (FITC-conjugated) a platelet marker and either anti-human CD4 (PE-  
14 conjugated) or anti-human CD8 (PE-conjugated), T lymphocyte markers for 1 hour  
15 at 25°C. Samples were washed twice, resuspended in PBS containing 4% of  
16 paraformaldehyde, and kept at 4°C prior to analysis. Flow cytometry was  
17 performed using a FACSCalibur analyzer, and data were analyzed using FlowJo  
18 software. Data were analyzed by gating for T cells (CD4+ and CD8+). Platelet and  
19 either CD4+ or CD8+ cell aggregates were discriminated by forward and side light  
20 scatter and identified by their positive staining with PE anti-CD41 and FITC anti-  
21 CD4 or CD8. Events double positive for PE and FITC identified platelet-CD4+T  
22 cell aggregates or platelet-CD8+ T cell aggregates and were recorded as a  
23 percentage of a total of 20,000 gated CD4+ or CD8+T cells (Supplemental Figure  
24 1).

1

2 *Platelet factor 4 (PF4) and soluble P-selectin measurement*

3 Co-culture supernatant (100µl) was collected by centrifugation (5,000g for 10  
4 minutes) each day from day 1 to 5. To detect PF4 and soluble p-selectin  
5 concentrations, corresponding ELISA kits (Sigma) were used. Samples were  
6 diluted 1:10 with a buffer provided in the kit. Samples and standard (100µl) were  
7 added to a 96-well plate coated with either anti-human PF4 or anti-human P-  
8 selectin antibody. The loaded plate was covered and incubated overnight at 4°C  
9 with gentle shaking. All the following steps were performed with gentle shaking  
10 and the plate was washed four times between each step. First, biotinylted antibody  
11 was added and the plate was incubated at RT for 1 hour. Second, wells were  
12 incubated with HRP-Streptavidin solution for 45 minutes at RT. Third, the  
13 substrate reagent was added for 30 minutes at RT. Finally, the reaction was  
14 stopped using the kit provided stop solution and the absorbance immediately read  
15 at 450nm using a micro-plate reader.

16

17 *Statistical analysis*

18 Each treatment group included four or more donors ( $n \geq 4$ ), based on power  
19 calculations and work performed previously [17-19]. Each independent experiment  
20 was performed using platelets and PBMCs isolated from one donor. PBMCs and  
21 platelets from 4 donors were isolated, co-cultured, stimulated and analyzed.  
22 Differences among groups were analyzed using a one-way ANOVA test. The analysis  
23 was performed in an unpaired fashion. Bonferroni's Multiple Comparison Test was

1 used as a posttest analysis.  $P < 0.05$  was considered to be significant. Data are  
2 reported as mean  $\pm$  standard error of the mean (S.E.M.) for each group.

### 3 **Results**

#### 4 **Platelets are viable and functional after isolation**

5 Prior to co-culturing the cells, we determined whether platelets were viable after  
6 isolation. As phosphatidylserine exposure, and subsequent Annexin V binding is a  
7 marker of cellular apoptosis and platelet activation, we investigated Annexin V-  
8 binding on platelet cell surface using flow cytometry (Table 1). Analysis of Annexin  
9 V-binding in recently isolated platelets was identified as  $4.1 \pm 0.2\%$  positive  
10 platelets, indicating that 96% of the platelets were 'classed' as viable at day 0. Next  
11 we determined whether freshly isolated platelets (day 0) were functional by  
12 stimulating them with 2MesADP (100nM) for 5 minutes. Unstimulated resting  
13 platelets did not show any notable surface expression of p-selectin when  
14 compared with the isotype control. As expected, we observed a significant  
15 increase in P-selectin surface expression following platelet stimulation with  
16 2MesADP ( $35.5 \pm 9.5\%$  positive cells compared to both resting/unstimulated  
17 platelets and isotype control,  $n = 4$ ). These data suggest that platelets were viable  
18 and functional at day 0.

19

#### 20 **PBMCs are viable after isolation**

21 Similarly for PBMCs, cell viability after isolation (day 0) was analyzed using  
22 Annexin V binding as a marker of apoptosis, and propidium iodide (PI) as a marker  
23 for necrosis. Data were analyzed as % of cells positive for Annexin V or Propidium

1 iodide or both. We observed  $5.2 \pm 0.3\%$  cells positive for Annexin V binding and  
2  $2.1 \pm 0.2\%$  positive cells for PI staining ( $n = 4$ ), suggesting that PBMC cells, like  
3 platelets, were also  $>95\%$  viable at day 0. To determine the T lymphocyte  
4 population at day 0, we also evaluated the % of CD4+ and CD8+ populations using  
5 flow cytometry. In line with findings of other groups, we obtained population sizes  
6 of  $34.5 \pm 2.5\%$  for CD4+ and  $17.5 \pm 3.2\%$  for CD8+ ( $n = 4$ ).

7

### 8 **Platelets are viable and functional at all time points**

9 Platelets are anucleated cells with a limited *in vivo* life span of 7-10 days. This  
10 makes platelets difficult cells to culture. Therefore we determined whether *ex vivo*  
11 prolonged culture (5 days) altered platelet viability. To achieve this we evaluated  
12 the % of Annexin V binding on the platelet cell surface, through 5 days of *ex vivo*  
13 culture (Table 1). Data are shown in Table 1 as a % of platelets expressing Annexin  
14 V. As anticipated, we observed an increased in Annexin V binding over time  
15 throughout the co-culture compared to day 0, with up to  $30 \pm 3\%$  Annexin V binding  
16 on day 5. Indicating that despite these increases, at day 4 and 5,  $\sim 70\%$  of the  
17 platelets are still classed as viable (Annexin V negative).

18

19

20

21

22

23

24

1

2 **Table 1** Phosphatidylserine exposure and Annexin V binding in platelets was evaluated  
3 using flow cytometry. Data are expressed as % of platelets binding Annexin V. (n=4).  
4 Means  $\pm$  S.E.M. are shown.

<b>Days</b>	<b>Annexin V (%)</b>
<b>0</b>	4.1 $\pm$ 0.2%
<b>1</b>	15 $\pm$ 3
<b>2</b>	22 $\pm$ 5
<b>3</b>	26 $\pm$ 5
<b>4</b>	30 $\pm$ 4
<b>5</b>	30 $\pm$ 3

5

6

7 **Platelets are able to secrete soluble p-selectin and PF-4 upon 2Mes-ADP**  
8 **exposure from day 0 to day 5**

9 As platelets are anucleate cells and they can degranulate over time [20], we  
10 determined whether throughout culture platelets are still able to initiate granule  
11 secrete from day 1 to day 5. To achieve this aim, we measured markers for platelet  
12 secretion such as soluble p-selectin (Table 2) and PF-4 (Table 3) in the  
13 supernatant throughout the 5 day culture using commercial ELISA kits. Platelet  
14 supernatant was collected before (unstimulated) and after stimulation with  
15 2MesADP (100nM) for 5 minutes (stimulated). Compared to levels of P-selectin  
16 and PF4 released following stimulation with 2Mes-ADP in freshly isolated platelets,  
17 platelet degranulation in response to agonist, was reduced throughout the 5 Day  
18 culture (Table 2 and 3). We observed a culture-mediated increase in both platelet

1 P-selectin and PF4 release in unstimulated cultured platelets compared to Day 0.  
 2 However, despite this low lying activation, a statistically significant increase in the  
 3 secretion of soluble p-selectin (Table 2) and PF4 (Table 3) in the supernatant  
 4 following stimulation by 2MeSADP was observed compared to unstimulated  
 5 samples at all time-points throughout culture (Table 2 and 3,  $P < 0.01$  and  $P < 0.05$ ;  
 6 cultured unstimulated platelets vs platelets activated with 2Mes-ADP,  $**p < 0.01$  and  $*p$   
 7  $< 0.05$ ,  $n = 4$ ). These data suggest that whilst reduced compared to non-cultured  
 8 platelets, cultured platelets can respond to ADP stimulation at all time-point of the  
 9 co-culture.

10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20

**Table 2:** content of soluble p-selectin in supernatant of platelets cultured alone from day 0 to day 5. Supernatant from platelets before and after stimulation with 2Mes-ADP (100nM, 5 minutes). At day 0, unstimulated platelets did not secrete idetectable levels of soluble p-selectin. Data are expressed as pg/mL  $\pm$  S.E.M. Comparisons are made between cultured unstimulated platelets vs platelets activated with 2Mes-ADP,  $**p < 0.01$  and  $*p < 0.05$ ,  $n = 4$ ).

	Unstimulated	2Mes-ADP stimulated
Day 0	0	168370 $\pm$ 13342**
Day 1	951 $\pm$ 70	3700 $\pm$ 35*
Day 2	885 $\pm$ 37	3370 $\pm$ 200 *
Day 3	825 $\pm$ 61	1966 $\pm$ 411*
Day 4	871 $\pm$ 72	1690 $\pm$ 63*
Day 5	998 $\pm$ 316	1621 $\pm$ 56*

21  
 22  
 23  
 24  
 25



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12

**Table 3:** the content of PF-4 in the supernatant of platelets cultured alone from day 0 to day 5. Supernatant from unstimulated platelets and platelets stimulated with 2Mes-ADP (100nM, 5 minutes) were measured. At day 0, unstimulated platelets did not secrete any detectable levels of PF4. Data are expressed as pg/mL  $\pm$  S.E.M. Comparisons are made between cultured unstimulated platelets vs platelets activated with 2Mes-ADP,  $**p < 0.01$  and  $*p < 0.05$ ,  $n = 4$ ).

	Unstimulated	2Mes-ADP stimulated
Day 0	0	22498.6 $\pm$ 1128.5**
Day 1	3920 $\pm$ 1385	15419 $\pm$ 4472*
Day 2	4495 $\pm$ 1771	15679 $\pm$ 3647*
Day 3	4039 $\pm$ 1086	14432 $\pm$ 3288*
Day 4	4215 $\pm$ 436	14812 $\pm$ 3902*
Day 5	4779 $\pm$ 592	15245 $\pm$ 4010*

13  
14

**PBMC proliferation is altered when PBMC were co-cultured with platelets depending on the stimuli**

15  
16  
17 The Alamar blue assay was used to determine PBMC proliferation. Proliferation was analyzed every day from day 1 to 5 (Table 4) in PBMCs cultured alone or co-cultured with platelets. Data are shown as proliferation index; the absorbance of stimulated cells versus unstimulated untreated PBMC. As expected treatment of PBMCs with CD3/28 antibodies or PHA resulted in a significant increase in proliferation index compared to unstimulated PBMC controls throughout the 5 days of culture (Table 4). Interestingly, whilst similar patterns of increased PBMC proliferation were observed following stimulation with CD3/28 antibodies or PHA

1 during co-culture with platelets, platelet-PBMC co-culture resulted in some  
 2 significance changes to PBMC proliferation profiles when compared to PMBCs  
 3 cultured alone. Under unstimulated conditions, PBMC proliferation in co-culture  
 4 with platelets was significantly increased at day 2 and 3 compared to unstimulated  
 5 PBMC in culture alone (Table 4,  $P < 0.05$ , unstimulated PBMC versus  
 6 unstimulated PBMC + platelets at day 2 and 3). However, upon stimulation with  
 7 anti-CD3-28, PBMC proliferation was observed to be significantly lower when cells  
 8 were co-cultured with platelets than when cultured alone from day 1 to 4 (Table 4,  
 9  $P < 0.05$ , unstimulated PBMC versus unstimulated PBMC + platelets at day 1, 2,  
 10 3 and 4). No changes in proliferation patterns were noted when co-cultured PBMCs  
 11 were stimulated with PHA compared to PBMCs cultured alone (Table 4).

12

13 **Table 4 PBMCs are viable at all time-points when cultured alone or with platelets.**

14 Cells were cultured without stimuli (unstimulated) or stimulated with PHA or anti-  
 15 CD3/CD28 for 5 days. Cell proliferation was analyzed using Alamar blue. Data are shown  
 16 as proliferation index, such as the absorbance of stimulated cells versus unstimulated  
 17 PBMC Means  $\pm$  S.E.M. are shown. (comparisons are made between PBMC + platelets  
 18 vs PBMC alone,  $*p < 0.05$ ,  $n = 4$ ).

19

Days	PBMC Unstimulated	PBMC + platelets Unstimulated	PBMC + CD3/28	PBMC + platelets + CD3/28	PBMC + PHA	PBMC + platelets + PHA
1	1 $\pm$ 0	0.96 $\pm$ 0.13	2.37 $\pm$ 0.21	1.97 $\pm$ 0.20*	1.82 $\pm$ 0.08	2.28 $\pm$ 0.19
2	1 $\pm$ 0	1.25 $\pm$ 0.19*	3.45 $\pm$ 0.19	1.96 $\pm$ 0.18*	3.01 $\pm$ 0.11	2.59 $\pm$ 0.14
3	1 $\pm$ 0	1.26 $\pm$ 0.16*	3.60 $\pm$ 0.12	2.30 $\pm$ 0.17*	3.31 $\pm$ 0.28	2.93 $\pm$ 0.14

<b>4</b>	1 ± 0	0.92 ± 0.15	2.39 ± 0.33	1.84 ± 0.22*	1.87 ± 0.08	2.12 ± 0.12
<b>5</b>	1 ± 0	1.01 ± 0.13	2.30 ± 0.14	2.32 ± 0.15	1.80 ± 0.37	2.23 ± 0.13

1

2

3

4 **When PBMCs were co-cultured with platelets, changes in CD4+ and CD8+**  
5 **population were observed in a time and stimuli-dependent manner**

6 Next the CD4+ and CD8+ population were analyzed in PBMC cultured alone (Fig  
7 2A and C) or with platelets (Fig 2B and D) every day from day 1 to day 5,  
8 unstimulated or in the presence of anti-CD3-28 or PHA. In unstimulated PBMCs,  
9 the CD4+ population significantly decreased during the 5 days (Fig 2A) compared  
10 to Day 0 (Fig. 2A,  $P < 0.05$ , Unstimulated PBMC at day 2, 3, 4 and 5 versus  
11 unstimulated PBMC at day 0). When cells were stimulated with anti-CD3-28  
12 antibodies, the CD4+ population significantly increased from day 2 to 3 (Fig. 2A,  
13  $P < 0.05$ , CD3-28-stimulated PBMC at day 2 and 3 and 4 versus unstimulated  
14 PBMC at day 0). Similarly, when cells were exposed to PHA, the CD4+ population  
15 increased from day 2 and 3 (Fig. 2A,  $P < 0.05$ , PHA-stimulated PBMC at day 2 and  
16 3 versus unstimulated PBMC at day 0). Interestingly when PBMCs were co-  
17 cultured with platelets (Fig 2B), the CD4+ population changed in a similar pattern  
18 to when PBMCs were cultured alone. In the presence of platelets, the CD4+  
19 population of unstimulated PBMCs significantly decreased during the 5 days of co-  
20 culture (Fig 2B) compared to Day 0 (Fig. 2B,  $P < 0.05$ , Unstimulated PBMC at day  
21 2 and 3 versus unstimulated PBMC at day 0). When cells were stimulated with

1 either anti-CD3-28 antibodies or PHA in co-culture, the CD4<sup>+</sup> population  
2 significantly increased at day 2.

3 In contrast, in unstimulated PBMCs cultured alone, the CD8<sup>+</sup> population did not  
4 increase or decrease during the 5 days of culture (Fig 2C). When PBMCs were  
5 stimulated with anti-CD3/28 antibodies, the CD8<sup>+</sup> population augmented,  
6 significantly at day 2 and 4 (Fig 2C  $P < 0.05$ , anti-CD3/28-stimulated PBMC at day  
7 2 and 4 versus unstimulated PBMC at day 0). Similarly, when exposed to PHA, the  
8 CD8<sup>+</sup> population significantly increased from days 2 to 4 (Fig. 2C,  $P < 0.05$ , PHA-  
9 stimulated PBMC at day 2, 3 and 4 versus unstimulated PBMC at day 0). In  
10 comparison, when PBMCs were co-cultured with platelets (Fig 2D at day 0), the  
11 CD8<sup>+</sup> population significantly increased only at day 3 when cells were stimulated  
12 with anti-CD3/28 antibodies (Fig 2C  $P < 0.05$ , anti-CD3/28 -stimulated PBMC at  
13 day 3 versus unstimulated PBMC at day 0) whilst no significant changes in the  
14 CD8<sup>+</sup> population was observed following treatment with PHA in co-culture  
15 conditions. Taken together, these data indicate that T cell activator induced  
16 changes in the CD8<sup>+</sup> population are limited when PBMCs are co-cultured with  
17 platelets compared to when cells were cultured alone in a stimuli dependent  
18 manner. Unstimulated platelets were not expected to alter T cells, as they do not  
19 express P-selectin at their surface and are therefore unable to interact with the T  
20 cells. This may have implications for future use of PHA as a T cell activator in this  
21 model.



22 We also compared CD4<sup>+</sup> and CD8<sup>+</sup> populations for each of the conditions tested  
23 (unstimulated, antibodies anti-CD3/28, PHA) for PBMCs alone and when co-



1 cultured with platelets for 5 days. Results are shown in Supplemental Fig 1 and 2,  
2 indicating that changes in PBMC population when co-cultured with platelets are  
3 time and stimuli-dependent.

4

5

**Figure 2. CD4+ and CD8+ population when PBMCs are co-cultured alone or with platelets.** PBMCs were cultured without stimuli (unstimulated) or stimulated with anti-CD3/CD28 or PHA for 5 days. PBMCs were cultured alone (**A** and **C**) or co-cultured with platelets (**B** and **D**). Cell populations positive to CD4 (**A** and **B**) and CD8 (**C** and **D**) were determined using flow cytometry every day from day 0 to 5. Data are expressed as mean of the fraction of cells among PBMC (%)  $\pm$  S.E.M. (\* $p < 0.05$ ,  $n = 4$ ).





1

2

3 **Platelets are functional throughout the culture and express p-selectin on cell**  
 4 **surface**

5 Upon activation, platelets express p-selectin on their cell membrane [21], and this  
 6 surface marker is essential for cell-cell interaction between platelets and white  
 7 blood cells [22]. To enable full characterisation of this model, we determined

1 changes in p-selectin surface expression in platelets, when cultured alone or in co-  
2 culture with PBMC in absence or presence of CD3-28 or PHA for 5 days (Fig 3).  
3 P-selectin surface expression was measured using flow cytometry. As platelets  
4 have a life span of 7-10 days *in vivo*, we also studied whether platelets could still  
5 be activated by exposure to 2Mes-ADP (100nM for 5 mins) when cultured alone in  
6 the presence of anti-CD3/28 antibodies or PHA to ascertain whether the platelets  
7 were still able to be activated and functional normally after 5 days in culture  
8 (Fig.3A). Interestingly, despite our observations of a culture mediated-increase in  
9 the released of soluble p-selectin when platelets were cultured alone in the  
10 absence of ADP stimulation, no significant changes in expression of p-selectin on  
11 the cell surface was observed in comparison to the isotype control. In addition, no  
12 significant difference in P-selectin surface expression levels was noted when  
13 platelets were cultured in an unstimulated environment compared with platelets  
14 cultured with anti-CD3-28 antibodies or PHA, indicating anti-CD3-28 and PHA do  
15 not induce platelet activation in culture. In contrast stimulation with 2Mes-ADP  
16 caused an increase in surface P-selectin expression (Figure 3A). When platelets  
17 were cultured alone under all the conditions analyzed (unstimulated, + CD3/28  
18 antibodies or +PHA), the 2MesADP-induced increase in surface p-selectin  
19 expression was not significantly different throughout the 5 day culture, from day 1  
20 to day 5 (Fig. 3A), indicating platelets were capable of activation throughout  
21 culture. Overall, these data indicate that platelets are able to respond to agonist  
22 stimulation and express surface p-selectin throughout 5 days of culture under all  
23 of the conditions investigated.



1 Having confirmed platelet viability in culture, we analyzed platelet p-selectin  
2 expression, when platelets were co-cultured with PBMCs under unstimulated  
3 conditions or PBMCs activated with CD3/28 or PHA (Fig 3B). Platelet surface P-  
4 selectin levels were observed to be higher in platelets co-cultured with PBMCs  
5 treated with CD3/CD28 antibodies compared to unstimulated PBMCs at days 3  
6 and 4 (Fig. 3A,  $P < 0.05$ , platelets + CD3/28-stimulated PBMC at day 3 or 4 versus  
7 platelets +unstimulated PBMC at day 3 or 4). Similarly, when platelets were  
8 cultured with PBMCs activated with PHA, P-selectin expression was also found to  
9 be higher than when platelets were cultured in an unstimulated PBMC environment  
10 at day 3 and 5 (Fig. 3A,  $P < 0.05$ , platelets + PHA-stimulated PBMC at day 3 or 5  
11 versus platelets +unstimulated PBMC at day 3 or 5). Given that no p-selectin  
12 expression is observed when platelets are cultured alone with CD3/CD28  
13 antibodies or PHA, taken together these data suggest that CD3/C28 antibodies  
14 and PHA elicit activation of platelets via activation of PBMCs.

15 These observations of increased P-selectin exposure in platelets co-cultured with  
16 stimulated PBMC, compared to unstimulated PBMC (Figure 3B) at days 3 and 4  
17 suggest an increased crosstalk between platelets and activated PBMCs at this  
18 time points. Thereby indicating this co-culture model allows investigation of T  
19 lymphocyte mediated activation of platelets.

20


21

22


23




**Figure 3. Platelets surface expression of p-selectin and the ability to shed soluble p-selectin are both maintained throughout the culture.** Platelets were cultured alone (A) or co-cultured (B) with PBMC in unstimulated environment or with anti-CD3/CD28 or PHA for 5 days. P-selectin expression on platelet surface was detected using flow cytometry every day from day 0 to 5. (A) P-selectin surface expression was analyzed in platelets co-cultured with PBMCs. (B) P-selectin surface expression was analyzed in platelets cultured alone and activated with 2Mes-ADP exposure (100nM – 5 mins). Data are expressed as the mean of the fraction of positive cells among platelets (%)  $\pm$  S.E.M. ( $*p < 0.05$ ,  $n = 4$ ). Platelets were co-cultured alone or with PBMC in unstimulated environment (C) or with anti-CD3/CD28 (D) or PHA (E) for 5 days. Soluble P-selectin concentration in the supernatant was analyzed using an ELISA kit every day from day 1 to 5. Platelets alone (patter bars), platelets cultured with PBMC (white bars) and platelets activated with 2Mes-ADP (gray bars, 100nM – 5 mins) were analyzed. Soluble P-selectin concentration by ADP-activated platelets after isolation (day 0) was 168370  $\pm$  13342. Data are expressed as pg/mL  $\pm$  S.E.M. ( $*p < 0.05$ ,  $n = 4$ ).

**A**



**B**



**C****D****E**

1 **Platelets maintain the ability to shed soluble p-selectin throughout the co-**  
2 **cultures**

3 P-selectin is not only expressed on the platelet membrane upon activation, but it  
4 is also shed in a soluble form and on platelet microparticles. During optimization  
5 of our culture conditions, we identified a culture mediated increase in release of  
6 soluble p-selectin levels, compared to non-cultured platelets, but we demonstrated  
7 platelets were still responsive to agonist stimulation, with increased p-selectin  
8 release in response to stimulation by 2Mes-ADP (Table 2). To determine whether  
9 platelets still maintain their responsiveness to agonist stimulation in co-culture,  
10 changes in soluble p-selectin concentrations (soluble form + p-selectin contained  
11 in microparticles) in the supernatant throughout the co-culture with PBMCs was  
12 investigated (Fig. 3). We analyzed levels of soluble p-selectin in the supernatant  
13 every day from day 1 to 5, when platelets were cultured alone or with PBMCs (Fig  
14 3) in unstimulated conditions (Fig 3C) or treated with CD3-28 antibodies (Fig 3D)  
15 or PHA (Fig 3E). We also determined whether platelets could shed p-selectin upon  
16 activation following 2Mes-ADP activation (100nM, 5 mins). Soluble P-selectin  
17 concentration following 2MesADP stimulation of platelets after isolation (day 0)  
18 was  $168370 \pm 13342$  pg/mL compared to  $1831 \pm 142$  pg/mL in unstimulated  
19 platelets after isolation (day 0). In unstimulated PBMC-platelet co-culture  
20 conditions (Fig 3A), soluble P-selectin was significantly increased compared to  
21 platelets in culture alone, at all time points (Fig. 3C,  $P < 0.05$ , platelets  
22 unstimulated vs platelets + PBMS or platelets + 2Mes-ADP). Levels of P-selectin  
23 released following 2MeSADP stimulation were significantly higher than those shed

1 by platelets when co-cultured with unstimulated PBMCs at day 1 and 2 but not at  
2 days 3-5, when levels of P-selectin shed into the supernatant were similar (Fig.  
3 3C,  $P < 0.05$ , platelets + unstimulated PBMC vs platelets + 2Mes-ADP at day 1  
4 and 2). This could be a marker of platelet desensitization to stimulation by ADP  
5 over prolonged culture. These data suggest that cultured platelets were able to  
6 shed p-selectin throughout the whole co-culture upon activation with 2Mes-ADP or  
7 when co-cultured with unstimulated PBMC. Similar patterns of soluble P-selectin  
8 release were observed when platelets were cultured (alone or co-cultured with  
9 PBMCs) in the presence of T cell activators CD3/CD28 antibodies (Figure 3D) and  
10 PHA (Figure 3E). Soluble P-selectin was significantly increased when platelets  
11 were co-culture with PBMC upon CD3-28 antibody activation or PHA activation in  
12 comparison to when they were cultured alone (Fig. 3D,  $P < 0.05$ , platelets + CD3-  
13 28 activated PBMC vs platelets alone and Fig. 3E,  $P < 0.05$ , platelets + PHA  
14 activated PBMC vs platelets alone ) at day 1, 3, 4 and 5. When platelets were  
15 stimulated with 2Mes-ADP for 5 minutes, soluble P-selectin was not significantly  
16 different from the value of soluble P-selectin observed when platelets were co-  
17 cultured with PBMC and stimulated with CD3-28 antibodies or PHA (Fig. 3D and  
18 E). Taken together, these data indicate that the levels of platelet secreted p-  
19 selectin following co-culture with activated PBMCs were not significantly different  
20 to the levels of P-selectin secreted when platelets were activated by 2Mes-ADP,  
21 suggesting activated T lymphocytes are capable of activating platelets to a similar  
22 level as soluble platelet agonists.  
23

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

### **Platelet secretion is maintained throughout the co-culture**

Platelets communicate with other cells of the immune system through secreting soluble mediators. During assay optimization we identified culture-mediated activation of platelet PF4 release during 5 day culture, compared to non-cultured platelets, in the absence of agonist. Despite this low lying level of activation, platelets still maintained responsiveness to platelet agonists with 2Mes-ADP mediated increases in PF4 release identified throughout culture. To investigate whether platelets can maintain secretion in co-culture platelet secretion of PF4 was determined throughout the PBMC-platelet co-culture (Fig. 4). Platelet factor 4 (PF4) is exclusively secreted by platelets [23] and it has shown to contribute to platelets-CD4+T cell interaction *in vitro* [17]. PF4 secretion was analysed every day from day 1 to 5, when platelets were cultured alone and with PBMCs (Fig 4) in unstimulated conditions (Fig 4A) and following stimulation with CD3-28 antibodies (Fig 4B) or PHA (Fig 4C). To ensure platelets maintained their ability to secrete their granular contents throughout the 5 day culture platelet PF4 release was also determined following 2Mes-ADP stimulation (100nM – 5 mins – A,B and C, third bar). Similar to that observed with soluble P-selectin release, levels of PF4 were significantly increased when platelets were co-cultured with unstimulated PBMCs (Fig. 4A,  $P < 0.05$ , platelets + unstimulated PBMC vs platelets alone), indicating some PBMC mediated activation of platelets even in the absence of T cell activators. However, when platelets were stimulated with 2Mes-ADP, PF4



1 secretion was significantly elevated compared with untreated platelets and  
2 platelets co-cultured with unstimulated PBMC at all the time points tested (Fig. 4A,  
3  $P < 0.05$ , platelets + 2Mes-ADP vs platelets alone and platelets), thereby indicating  
4 that unstimulated PBMCs only cause low levels of PF4 release compared to  
5 stimulation by traditional platelet agonists and also highlights that platelets  
6 maintain their ability to secrete PF-4 over 5 day culture. In conditions where  
7 platelets in culture and co-culture with PBMCs were also treated with T cell  
8 activators CD3-28 antibodies (Figure 4B) or PHA (Figure 4C), secreted levels of  
9 PF4 was significantly increased when platelets were co-cultured with PBMCs  
10 compared to platelets cultured alone (Fig. 4B,  $P < 0.05$ , platelets + CD3-28  
11 activated PBMC vs platelets alone and Fig. 4C,  $P < 0.05$ , platelets + PHA activated  
12 PBMC vs platelets alone), and to higher levels than that observed following co-  
13 culture with unstimulated PBMCs (Fig 4A) indicating T cell activator mediated  
14 activation of platelet PF4 secretion is primarily mediated through activation of T  
15 cells. Interestingly similar to that observed with soluble P-selectin release, when  
16 platelets were stimulated with 2Mes-ADP for 5 minutes in the presence of  
17 activators of T cells CD3/28 or PHA, PF4 secretion was higher than when platelets  
18 were cultured alone but no significant differences were observed in the levels of  
19 PF4 secreted in 2Mes-ADP stimulated platelets compared to that released by  
20 platelets co-cultured with activated PBMCs (Fig. 4B,  $P < 0.05$ , platelets + CD3/28  
21 2Mes-ADP vs platelets + CD3/28 and Fig. 4C,  $P < 0.05$ , platelets + PHA 2Mes-  
22 ADP vs platelets + CD3/28) (Fig. 4B and Figure 4C). Indicating T lymphocyte




1 mediated activation of platelets can elicit similar levels of PF4 secretion to those  
2 achieved via direct agonist stimulation of platelets.

3

4 **Figure 4. Platelet secretion is maintained throughout the co-culture.** Platelets were  
5 co-cultured alone or with PBMC in unstimulated environment (**A**) or with anti-CD3/CD28  
6 (**B**) or PHA (**C**) for 5 days. PF-4 concentration in the supernatant was analyzed using an  
7 ELISA kit every day from day 1 to 5. Platelets alone (patter bars), platelets cultured with  
8 PBMC (white bars) and platelets activated with 2Mes-ADP (gray bars, 100nM – 5 mins)  
9 were analyzed. PF-4 concentration by ADP-activated platelets immediately after isolation  
10 (day 0) was  $22498.6 \pm 1128.5$ . Data are expressed as  $\text{pg/mL} \pm \text{S.E.M.}$  ( $*p < 0.05$ ,  $n = 4$ ).



1



2

3

4


1 **Platelets and T lymphocytes aggregate in a time- and stimuli-dependent**  
2 **manner**


3 In addition to communication via secretion of soluble mediators, platelets also  
4 communicate with PBMCs through cell-cell interaction, e.g., by forming platelet-  
5 lymphocyte aggregates [3]. We therefore determined the ability of CD4<sup>+</sup> or CD8<sup>+</sup>  
6 T lymphocytes to form heterotypical aggregates with platelets during 5 day co-  
7 culture in the presence and absence of T cell activators CD3/28 or PHA (Figure  
8 5). When PBMCs were not stimulated, there was no significant change in the  
9 formation of platelets-CD4<sup>+</sup> (CD41<sup>+</sup>/CD4<sup>+</sup>) or platelet-CD8<sup>+</sup> (CD41<sup>+</sup>/CD8<sup>+</sup>)  
10 aggregate formation from day 1 to 5 of co-culture (Fig 5A). In contrast under  
11 conditions where PBMCs were stimulated with anti-CD3/28 antibodies, heterotypic  
12 aggregate formation of CD41<sup>+</sup>/CD4<sup>+</sup> aggregates progressively increased from  
13 day 1 to day 2 and 3 (Fig. 5B,  $P < 0.05$ , day 2 vs day 1 and day 3 vs day 1).  
14 Similarly, aggregate formation of CD41<sup>+</sup>/CD8<sup>+</sup> also increased from day 1 to day 2  
15 and 3 (Fig. 5B,  $P < 0.05$ , day 2 vs day 1 and day 3 vs day 1). Similar observations  
16 of CD41<sup>+</sup>/CD4<sup>+</sup> aggregate formation were also made following activation of  
17 PBMCs with PHA, (Fig. 5C,  $P < 0.05$ , day 2 vs day 1 and day 3 vs day 1).  
18 Interestingly however, in contrast to CD3/28, PHA stimulation resulted in no  
19 observed changes in CD41<sup>+</sup>/CD8<sup>+</sup> aggregate formation. These data suggest that  
20 platelet-CD4<sup>+</sup> and platelet-CD8<sup>+</sup> cell aggregates form early in PBMC-platelet co-  
21 culture in a time-dependent and stimuli-dependent manner.

22

23

**Figure 5. Platelet and T lymphocytes aggregate in a time- and stimuli-dependent manner.** Platelets and PBMCs were co-cultured in unstimulated environment (**A**) or with anti-CD3/CD28 (**B**) or PHA (**C**) for 5 days. Platelets-T cells aggregate formation was determined using flow cytometry. T cells were gated based on either CD4 or CD8 expression and cell shape, and data were analyzed based on the percentage of aggregates that express both CD41 and CD4 or CD41 and CD8. Aggregates were measured every day from day 1 to 5. Data are expressed as mean of the fraction of cells among T cells (%)  $\pm$  S.E.M. (\* $p < 0.05$ ,  $n = 4$ ).





1

2 **Discussion**

3 Platelets are highly interactive cells. Among others, platelets are known to  
 4 communicate with all types of leukocytes, either through soluble mediators or via  
 5 direct cell-cell contacts. These interactions have been studied *in vivo* using a  
 6 variety of animal models [8-11], which have the advantage of being able to reveal  
 7 platelet-leukocyte cross-talk in physiological milieus. *Ex vivo*, *in vitro* platelet-  
 8 leukocyte co-cultures, however, provide a useful platform to dissect these  
 9 mechanisms with easily adjustable culture conditions and settings using human  
 10 cells. We have developed an *in vitro* co-culture model that can mimic *in vivo*  
 11 platelet-leukocyte (specifically T cell) interaction using human cells, in a more  
 12 controlled environment that enables rapid and the most cost effective analysis of  
 13 the role of platelets in inflammation.

14 Platelets and leukocytes interact during inflammation through cell-cell interaction  
 15 [10-13, 24]. To enable characterization of the model, we monitored receptor  
 16 expression of P-selectin on the platelet surface, a key mediator of platelet-T cell

1 interaction, via the interaction of P-selectin on platelet surface and P-selectin  
2 glycoprotein ligand 1 (PSGL-1) on T cells [25]. Our data confirm that platelets were  
3 able to express p-selectin on the cell surface throughout the co-culture model,  
4 indicating the potential for cell-cell interactions in this *in vitro* model [22]. We have  
5 observed that the ability to form heterotypic platelet-T cell aggregates peaks at day  
6 3 during 5 day co-culture. This suggests that day 3 may be the best time point to  
7 use to investigate cell-cell interaction when using the co-culture methods described  
8 here. However, as platelet-leukocyte interactions are mediated by both cell-cell  
9 interaction and release of soluble mediators, our observations showing that  
10 secretion of inflammatory mediators was maintained throughout the culture period,  
11 indicates that it could be useful to include later time points of co-culture if studying  
12 the contribution of soluble factors to platelet and T cell signaling and interactions.  
13 Although platelets were shown to respond to ADP activation at all time-points, we  
14 observed a low-level culture-dependent activation of platelets. Whilst the level of  
15 activation is low, this could still lead to a level of PBMC activation during co-culture  
16 even in the absence of stimuli. Despite this, we did not observe any culture  
17 mediated platelet dependent changes in PBMCs. PBMC activation did not show  
18 any significant difference when comparing unstimulated PBMCs alone compared  
19 with unstimulated PBMCs co-cultured with platelets. We therefore propose that the  
20 observed low level of platelet activation that occurs during culture, does not  
21 significantly alter PBMCs in this model. However, in light of these  
22 considerations, when performing this model, we advise future users to 1) select  
23 earlier time points when possible; 2) include PBMCs cultured with platelets in the

1 absence of stimuli as a negative control. P-selectin is not only expressed on  
2 platelet cell surface but it is also shed by platelets upon activation as another key  
3 step in cell communication [5, 7, 26]. Our data confirm that p-selectin is also shed  
4 by platelets when activated by 2MesADP and when co-cultured with activated  
5 PBMC. This is particularly important as during inflammation platelets have shown  
6 to secrete microparticles (MP) [27] and exosomes [28] containing P-selectin *in vivo*  
7 and *in vitro*. MPs derived from platelets make up between 70 and 90% of the total  
8 circulating MPs [29]. Hence it is important to note that platelets maintain their ability  
9 to shed P-selectin in both its soluble form throughout 5 day culture. These data  
10 suggest that the *in vitro* model presented here has the potential to be used used  
11 to investigate soluble p-selectin as a method of cell communication. The model  
12 could be also used to study more specific changes in MP shedding.

13 Platelets store inflammatory mediators such as TGF- $\beta$ , RANTES, PF4 and IL-1 $\beta$   
14 [5, 6] that upon activation are secreted. Our data show that PF-4 (a reliable  
15 indicator of platelet specific secretion) [23] is secreted by platelets in this model  
16 when they were stimulated with 2MesADP, indicating that the ability of platelets to  
17 secrete their granular contents is maintained throughout culture and following co-  
18 culture with activated PBMCs. This further supports our observations that  
19 activated T cells are able to activate platelets and platelet secretion, and trigger  
20 cell-cell interaction in line with what we observed *in vivo*.

21 An increase in heterogenous aggregates between CD4<sup>+</sup> T cells or CD8<sup>+</sup> T cells  
22 and platelets have been observed in the blood of a number of patients and a variety  
23 of animal models [12, 13, 15]. This model provides an *in vitro* platform to

1 investigate platelet-T-cell aggregates *ex vivo*. We observed aggregate formation  
2 between CD4<sup>+</sup> or CD8<sup>+</sup> and platelets throughout the PBMC-platelet co-culture  
3 with a peak at day 2 and 3. Moreover, a recent paper reported that platelets  
4 diminished CD8<sup>+</sup> cell count and functions in a model of sepsis [30]. However, in  
5 other models, platelets have shown to increase CD8<sup>+</sup> cell population and cytokine  
6 production [31-33]. This is in line with our data that show changes in the CD8<sup>+</sup>  
7 population in presence and absence of platelets were stimuli-dependent. This  
8 discrepancy between diseases and models needs to be considered when selecting  
9 the most appropriate stimuli and conditions for use in this model.

10 While PBMCs have been successfully cultured, whether it is possible to culture  
11 platelets is still controversial. Due to their nature, it has always been thought that  
12 the optimal way to study platelets function is when freshly isolated. There are  
13 however, a number of studies that have investigated whether platelets can  
14 maintain some of their key functions when cultured for up to 7 days [34, 35]. All the  
15 studies reached different conclusions, but they all agree that platelet functions  
16 such as aggregation [34] and p-selectin expression [35, 36] can be affected when  
17 cultured. Our data suggest that under the conditions described here, secretion and  
18 p-selectin expression are still comparable during co-culture as reported previously.

19 However, it is important to note that some functions, such as heterotypic  
20 aggregation (platelet:T-cell) seem to be more affected over prolonged time in  
21 culture (days 4-5) [34].

22 All experimental models, both *in vitro* and *in vivo* have their limitations. Although  
23 we provide evidence of cell-cell interaction in culture (directly or through surface



1 receptors), this model cannot substitute the interaction of the cells *in vivo*. One  
2 limitation of the model is that the cells interact in a static /resting condition that is  
3 not representative of physiological conditions, specifically flow conditions. We  
4 were still able to detect both cell-cell interaction (aggregate formation) and  
5 communication through soluble factors (soluble p-selectin and PF-4), but this  
6 limitation needs to be considered and explored in future studies investigating cell  
7 interactions under conditions of shear such as under stirring conditions or within a  
8 flow circuit. It is also important to note, that whilst we demonstrate platelets are  
9 capable of responding to agonist stimulation and maintain 70% viability up to 5  
10 days in culture , as anucleated cells they likely do not fully retain all their features  
11 when cultured. In support of this, we demonstrated a low lying activation of  
12 platelets when cultured alone throughout this culture model. Whilst we observed  
13 no significant alteration in PBMC activation, despite this basal increase in platelet  
14 activity following culture, it is important to be aware of it and consider that culture  
15 conditions may impact PBMCs' activation and proliferation while using this model.  
16 To overcome this problem, it is advised to perform shorter co-cultures where  
17 possible, we demonstrate increased platelet-leukocyte aggregate formation at day  
18 3, indicating, 72 hours of co-culture may be the most ideal condition to use. and to  
19 always include a control of unstimulated platelets cultured alone to determine  
20 whether their low lying activation is significant. We did not detect any changes in  
21 platelet functions when cultured alone with anti-CD3/28 or PHA, compared with an  
22 unstimulated environment, however it is advised to include the necessary controls  
23 with any stimuli used.

1 This co-culture system supports *ex vivo* evaluations of platelet-leukocyte  
2 interactions over time under defined conditions, to interrogate effects of platelet  
3 aging during inflammation. Whilst we accept this *ex vivo*, *in vitro* model has its  
4 limitations, the model offers a number of advantages. As an all *in vitro* model, this  
5 co-culture supports the principles of the 3Rs, replace, reduce and refine [37-39]  
6 and enables the translation of *in vivo* data obtained from animal studies to human  
7 cells. These experiments in human cells not only increase the relevance of the  
8 data from animals to humans, but they can be used in place of animal models,  
9 reducing the number animals sacrificed. Moreover, in instances where it is  
10 necessary to use animal platelets and PBMCs, this model can be used, reducing  
11 the pain that animals would be exposed to in the animal model of a disease (partial  
12 replacement). This model is adaptable and can be modified to enable researchers  
13 to investigate the effects of current and novel drug therapies on platelet-leukocyte  
14 interactions whilst elucidating the specific mechanistic pathways involved. Here we  
15 focused on the interaction between platelets and T lymphocytes, but use of PBMCs  
16 offers the opportunity to study the interaction between platelets and other immune  
17 cells such as dendritic cells and monocytes. Further variations can also be  
18 introduced, by isolating CD4+ or CD8+ or dendritic cells and using these in the co-  
19 cultures instead of PBMCs.

20 In conclusion, we present a characterized *in vitro* model of platelet-PBMC  
21 interactions where platelets and PBMCs communicate via cell-cell interaction and  
22 secretion similarly to their methods of *in vivo* communication. Hence this model

1 can be used as an *in vitro* model to confirm and/or support *in vivo* results for the  
2 investigation of the role of platelet ageing in the inflammatory response.

3

4

### 5 **Conflict of interest**

6 The authors have no conflict of interest to disclose.

7

### 8 **Funding**

9 This work was supported by the American Heart Association, grant  
10 16SDG26980003 to EL and by the National Institute of Health, grant AI156627-01  
11 to EL and a British Heart Foundation project grant PG/2019/34798 and Royal  
12 Society International Exchange award IES\R2\212065 to AJU.

13

### 14 **Author contributions**

15 S.A collected materials, performed experiments and analyzed data. E.L. designed  
16 the research study, analyzed data and wrote the manuscript. N.L. analyzed data  
17 and wrote the manuscript. A.J.U analyzed data and wrote the manuscript. All  
18 authors reviewed and approved the final manuscript.

19

### 20 **References**

- 21 1. Ben Addi A, Cammarata D, Conley PB, Boeynaems JM, Robaye B: **Role of the**  
22 **P2Y12 receptor in the modulation of murine dendritic cell function by ADP.** *J*  
23 *Immunol* 2010, **185**:5900-5906.
- 24 2. Micklewright JJ, Layhadi JA, Fountain SJ: **P2Y12 receptor modulation of ADP-**  
25 **evoked intracellular Ca(2+) signalling in THP-1 human monocytic cells.** *Br J*  
26 *Pharmacol* 2018, **175**:2483-2491.

- 1 3. Li N: **Platelet-lymphocyte cross-talk.** *J Leukoc Biol* 2008, **83**:1069-1078.
- 2 4. Wang L, Jacobsen SE, Bengtsson A, Erlinge D: **P2 receptor mRNA expression**  
3 **profiles in human lymphocytes, monocytes and CD34+ stem and progenitor**  
4 **cells.** *BMC Immunol* 2004, **5**:16.
- 5 5. Liverani E, Kilpatrick LE, Tsygankov AY, Kunapuli SP: **The role of P2Y(1)(2)**  
6 **receptor and activated platelets during inflammation.** *Curr Drug Targets* 2014,  
7 **15**:720-728.
- 8 6. Semple JW, Italiano JE, Jr., Freedman J: **Platelets and the immune continuum.**  
9 *Nat Rev Immunol* 2011, **11**:264-274.
- 10 7. Manne BK, Xiang SC, Rondina MT: **Platelet secretion in inflammatory and**  
11 **infectious diseases.** *Platelets* 2017, **28**:155-164.
- 12 8. Asaduzzaman M, Lavasani S, Rahman M, Zhang S, Braun OO, Jeppsson B,  
13 Thorlacius H: **Platelets support pulmonary recruitment of neutrophils in**  
14 **abdominal sepsis.** *Crit Care Med* 2009, **37**:1389-1396.
- 15 9. Hagiwara S, Iwasaka H, Hasegawa A, Oyama M, Imatomi R, Uchida T, Noguchi  
16 T: **Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates**  
17 **LPS-induced systemic inflammation in a rat model.** *Shock* 2011, **35**:289-292.
- 18 10. Liu Y, Gao XM, Fang L, Jennings NL, Su Y, Q X, Samson AL, Kiriazis H, Wang  
19 XF, Shan L, et al: **Novel role of platelets in mediating inflammatory responses**  
20 **and ventricular rupture or remodeling following myocardial infarction.**  
21 *Arterioscler Thromb Vasc Biol* 2011, **31**:834-841.
- 22 11. Liverani E, Rico MC, Tsygankov AY, Kilpatrick LE, Kunapuli SP: **P2Y12**  
23 **Receptor Modulates Sepsis-Induced Inflammation.** *Arterioscler Thromb Vasc*  
24 *Biol* 2016, **36**:961-971.
- 25 12. Zamora C, Canto E, Nieto JC, Ortiz MA, Diaz-Torne C, Diaz-Lopez C, Llobet JM,  
26 Juarez C, Vidal S: **Functional consequences of platelet binding to T**  
27 **lymphocytes in inflammation.** *J Leukoc Biol* 2013, **94**:521-529.
- 28 13. Green SA, Smith M, Hasley RB, Stephany D, Harned A, Nagashima K, Abdullah  
29 S, Pittaluga S, Imamichi T, Qin J, et al: **Activated platelet-T-cell conjugates in**  
30 **peripheral blood of patients with HIV infection: coupling**  
31 **coagulation/inflammation and T cells.** *AIDS* 2015, **29**:1297-1308.
- 32 14. Zhu L, Huang Z, Stalesen R, Hansson GK, Li N: **Platelets provoke distinct**  
33 **dynamics of immune responses by differentially regulating CD4+ T-cell**  
34 **proliferation.** *J Thromb Haemost* 2014, **12**:1156-1165.
- 35 15. Bergmann CB, Hefele F, Unger M, Huber-Wagner S, Biberthaler P, van Griensven  
36 M, Hanschen M: **Platelets modulate the immune response following trauma by**  
37 **interaction with CD4+ T regulatory cells in a mouse model.** *Immunol Res* 2016,  
38 **64**:508-517.
- 39 16. Albayati S, Vemulapalli H, Tsygankov AY, Liverani E: **P2Y12 antagonism**  
40 **results in altered interactions between platelets and regulatory T cells during**  
41 **sepsis.** *J Leukoc Biol* 2020.
- 42 17. Tan S, Li S, Min Y, Gistera A, Moruzzi N, Zhang J, Sun Y, Andersson J,  
43 Malmstrom RE, Wang M, et al: **Platelet factor 4 enhances CD4(+) T effector**  
44 **memory cell responses via Akt-PGC1alpha-TFAM signaling-mediated**  
45 **mitochondrial biogenesis.** *J Thromb Haemost* 2020.

- 1 18. Gerdes N, Zhu L, Ersoy M, Hermansson A, Hjemdahl P, Hu H, Hansson GK, Li  
2 N: **Platelets regulate CD4(+) T-cell differentiation via multiple chemokines in**  
3 **humans.** *Thromb Haemost* 2011, **106**:353-362.
- 4 19. Hamzeh-Cognasse H, Cognasse F, Palle S, Chavarin P, Olivier T, Delezay O,  
5 Pozzetto B, Garraud O: **Direct contact of platelets and their released products**  
6 **exert different effects on human dendritic cell maturation.** *BMC Immunol* 2008,  
7 **9**:54.
- 8 20. Josefsson EC, Vainchenker W, James C: **Regulation of Platelet Production and**  
9 **Life Span: Role of Bcl-xL and Potential Implications for Human Platelet**  
10 **Diseases.** *Int J Mol Sci* 2020, **21**.
- 11 21. Murugappa S, Kunapuli SP: **The role of ADP receptors in platelet function.**  
12 *Front Biosci* 2006, **11**:1977-1986.
- 13 22. Abadier M, Ley K: **P-selectin glycoprotein ligand-1 in T cells.** *Curr Opin*  
14 *Hematol* 2017, **24**:265-273.
- 15 23. Slungaard A: **Platelet factor 4: a chemokine enigma.** *Int J Biochem Cell Biol*  
16 2005, **37**:1162-1167.
- 17 24. Liverani E, Mondrinos MJ, Sun S, Kunapuli SP, Kilpatrick LE: **Role of Protein**  
18 **Kinase C-delta in regulating platelet activation and platelet-leukocyte**  
19 **interaction during sepsis.** *PLoS One* 2018, **13**:e0195379.
- 20 25. Ley K, Kansas GS: **Selectins in T-cell recruitment to non-lymphoid tissues and**  
21 **sites of inflammation.** *Nat Rev Immunol* 2004, **4**:325-335.
- 22 26. Kim S, Kunapuli SP: **P2Y12 receptor in platelet activation.** *Platelets* 2011,  
23 **22**:56-60.
- 24 27. Puddu P, Puddu GM, Cravero E, Muscari S, Muscari A: **The involvement of**  
25 **circulating microparticles in inflammation, coagulation and cardiovascular**  
26 **diseases.** *Can J Cardiol* 2010, **26**:140-145.
- 27 28. Jiao Y, Li W, Wang W, Tong X, Xia R, Fan J, Du J, Zhang C, Shi X: **Platelet-**  
28 **derived exosomes promote neutrophil extracellular trap formation during**  
29 **septic shock.** *Crit Care* 2020, **24**:380.
- 30 29. Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O:  
31 **Platelets and infections - complex interactions with bacteria.** *Front Immunol*  
32 2015, **6**:82.
- 33 30. Guo L, Shen S, Rowley JW, Tolley ND, Jia W, Manne BK, McComas KN,  
34 Bolingbroke B, Kosaka Y, Krauel K, et al: **Platelet MHC class I mediates CD8+**  
35 **T-cell suppression during sepsis.** *Blood* 2021, **138**:401-416.
- 36 31. Chapman LM, Aggrey AA, Field DJ, Srivastava K, Ture S, Yui K, Topham DJ,  
37 Baldwin WM, 3rd, Morrell CN: **Platelets present antigen in the context of MHC**  
38 **class I.** *J Immunol* 2012, **189**:916-923.
- 39 32. Loria GD, Romagnoli PA, Moseley NB, Rucavado A, Altman JD: **Platelets**  
40 **support a protective immune response to LCMV by preventing splenic**  
41 **necrosis.** *Blood* 2013, **121**:940-950.
- 42 33. Zamora C, Canto E, Nieto JC, Bardina J, Diaz-Torne C, Moya P, Magallares B,  
43 Ortiz MA, Julia G, Juarez C, et al: **Binding of Platelets to Lymphocytes: A**  
44 **Potential Anti-Inflammatory Therapy in Rheumatoid Arthritis.** *J Immunol*  
45 2017, **198**:3099-3108.

- 1 34. Rock G, Freedman M, Hamilton C, Bormanis J: **New methods showing in vitro**  
2 **changes of platelets.** *Transfus Apher Sci* 2006, **35**:145-149.
- 3 35. Wang J, Yi X, Liu M, Zhou Q, Ren S, Wang Y, Yang C, Zhou J, Han Y:  
4 **Correlation between the In Vitro Functionality of Stored Platelets and the**  
5 **Cytosolic Esterase-Induced Fluorescence Intensity with CMFDA.** *PLoS One*  
6 2015, **10**:e0138509.
- 7 36. Akay OM, Gunduz E, Basyigit H, Gulbas Z: **Platelet function testing during 5-**  
8 **day storage of single and random donor plateletpheresis.** *Transfus Apher Sci*  
9 2007, **36**:285-289.
- 10 37. Eggel M, Wurbel H: **Internal consistency and compatibility of the 3Rs and 3Vs**  
11 **principles for project evaluation of animal research.** *Lab Anim* 2021, **55**:233-  
12 243.
- 13 38. Hubrecht RC, Carter E: **The 3Rs and Humane Experimental Technique:**  
14 **Implementing Change.** *Animals (Basel)* 2019, **9**.
- 15 39. Kirk RGW: **Recovering The Principles of Humane Experimental Technique:**  
16 **The 3Rs and the Human Essence of Animal Research.** *Sci Technol Human*  
17 *Values* 2018, **43**:622-648.
- 18  
19

20


## 21 **Supplemental data**

22

## 23 **Results**

24 To more extensively compare our data, we have now plotted CD4+ and CD8+  
25 populations for each conditons (unstimulated, antibodies anti-CD3/28, PHA) for  
26 PBMCs alone and when co-cultured with platelets for 5 days. Results are shown in  
27 Supplemental Fig 1 and 2. No change in CD4+ percentage of cells was observed  
28 when PBMCs were cultured with platelets as compared with they were cultured alone  
29 without stimuli (Supl Fig 1A) nor when PBMCs were co-cultured with platelets upon  
30 anti-CD3/28 stimulation (Supl Fig 1A). However, when PBMCs were stimulated with  
31 PHA, we noted a significant decrease in the CD4+ population, when cells were co-  
32 cultured with platelets at day 2 (Supl Fig 1C, PBMCs + CD3/28 vs PBMCs + platelets


1 + CD3/28). Similarly to what we noted in the CD4+ population, we did not noted any  
 2 significant change between PBMCs cultured alone or with platelets upon  
 3 unstimulated conditions (Supl Fig 2A). However, we observed a significant increase  
 4 in the percentage of the CD8+ population at day 3 when cultured with platelets as  
 5 compared with PBMCs + anti-CD3/28 cultured alone (Supl Fig 2B, PBMCs + CD3/28  
 6 vs PBMCs + platelets + CD3/28). On the other hand, when PBMCs were co-cultured  
 7 with platelets and stimulated with PHA, we noted a significant increase in the  
 8 percentage of the CD8+ population at day 2 and 4 (Supl Fig 2C, PBMCs + CD3/28  
 9 vs PBMCs + platelets + CD3/28 at day 2 and 4). This data suggest that changes in  
 10 PBMC population when co-cultured with platelets are time and stimuli-dependent.  
 11 every day from day 0 to 5. Data are expressed as mean of the fraction of cells among PBMC  
 12 (%)  $\pm$  S.E.M. (\* $p < 0.05$ , PBMCs + CD3/28 vs PBMCs + platelets + CD3/28  $n = 4$ ).



13  
 14  
 15  
 16

1  
2  
3  
4  
5  
6  
7  
8  
9

**Supplemental Fig 2:** PBMCs were cultured without stimuli (unstimulated) (A) or stimulated with anti-CD3/CD28 (B) or PHA (C) for 5 days. PBMCs were cultured alone or co-cultured with platelets. Cell populations positive to CD8 were determined using flow cytometry every day from day 0 to 5. Data are expressed as mean of the fraction of cells among PBMC (%)  $\pm$  S.E.M. (\* $p < 0.05$ ,  $n = 4$ ).



10